Delivery Order SPE2DB22D2211-SPE2DB25FSCDU
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,376.00 to supply Gemtesa 75 mg tablets (90-count packaging) with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded a delivery order valued at $10,199.71 to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. AmerisourceBergen, headquartered...
- The Defense Logistics Agency awarded a $133,014.83 delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on September 16, 2025, with an ultimate completion date of September 17, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a $8,938.51 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of September 12, 2025. The award will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) at a ceiling value of $2,378.33. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on August 29, 2025, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency has awarded a delivery order valued at $10,816.44 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a $7,448.66 delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of Gemtesa 75 mg tablets (90 count). This is a firm fixed price, non-set-aside contract with a completion date of April 23, 2025, and performance to be executed in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger pharmaceutical supply agreement with the DLA. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $11,102.49 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on September 26, 2025, with completion scheduled for September 29, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,792.03 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on July 23, 2025, with completion scheduled for July 24, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical supply vehicle running through...
- The Defense Logistics Agency has awarded a delivery order valued at $104,511.07 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units). This firm fixed-price contract, which was not set-aside and competitively awarded, was executed on August 5, 2025, with an ultimate completion date of August 6, 2025. The place of performance is the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSCDUDelivery Order
The Defense Logistics Agency awarded a $45.5K delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical supply portfolio supporting military and veteran healthcare systems. As a critical vendor in the Defense Logistics Agency's Medical Supply Chain, the company supplies a wide range of pharmaceutical products and medical commodities across multiple therapeutic domains. Gemtesa is a medication used in the treatment of overactive bladder, reflecting the company's role in delivering specialized pharmaceuticals to support defense health operations. AmerisourceBergen's extensive federal contract history demonstrates its capability to fulfill competitive procurement requirements across diverse product categories, from generic medications to brand-name drugs and medical supplies, supporting the Defense Health Agency and other government healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $45.5k | 8/4/25 |